Hospital acquired pneumonia
Conditions
Interventions
Exposure group:Based on polymyxin B combined with Tigecycline treatment group
Control group:Treatment group based on polymyxin B
Control group:Treatment group based on Tigecycline
Sponsors
China-Japanese Friendship Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for hospital acquired pneumonia (HAP); 2. Positive microbiological reports during hospitalization include, but are not limited to, carbapenem-resistant; 3. Enterobacter (CRE) or carbapenem-resistant Acinetobacter baumannii (CRAB); 4. For patients with a survival time of >5 days, tigecycline is included in the antibiotic regimen and its continuous use time is >= 5 days; for patients with survival time = 48 hours, tigecycline is included in the antibiotic treatment regimen and its continuous use time needs to be >= half of the total treatment time; or other patients who believe that a reasonable treatment plan; 5. For patients with a survival time of >5 days, the antibiotic treatment regimen contains polymyxin B and its continuous use time is >= 5 days; for patients with a survival time of = 48 hours, the antibiotic treatment regimen contains polymyxin B and its continuous use time should be >= half of the total treatment time; or other patients who consider a reasonable treatment plan; 6. Antibiotic dosing regimens and courses of treatment meet the requirements of this study.
Exclusion criteria
Exclusion criteria: 1. Patients who die within 48 hours of use after tigecycline or a polymyxin B-based antibiotic regimen; 2. Other reasons that researchers believe are not suitable for this study, such as antibiotic medication confusion, difficult to analyze, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 28-day all-cause mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Other mortality;Ratio of treatment success and treatment failure in hospitalization;time to reach clinical stability;fever clearance time;Hospitalization time;Time to stay in the ICU;Mechanical ventilation time;Microbiological clearance rate;Discharge patients function status;The incidence of adverse reactions (normal renal function);Type of carbapenemase genotype that can be detected; | — |
Countries
China
Contacts
Public ContactBin Cao
China-Japanese Friendship Hospital
Outcome results
None listed